For most people with osteopenia, the safest approach is no drug at all. Osteopenia sits in a gray zone between normal bone density and osteoporosis, defined by a T-score between -1.0 and -2.5, and the majority of people in this range are better served by lifestyle changes than by medication. When drugs are warranted, oral bisphosphonates like alendronate and risedronate have the longest safety track record and are recommended as first-line therapy, though “safest” depends heavily on your individual health profile.
Most People With Osteopenia Don’t Need Medication
This is the most important point and the one that often gets buried. Pharmacological treatment is recommended for osteopenia only when your 10-year fracture risk crosses a specific threshold: 3% or greater for hip fracture or 20% or greater for any major osteoporotic fracture, calculated using a tool called FRAX that factors in your age, weight, smoking history, family history, and other variables. If you fall below those thresholds, guidelines call for nonpharmacologic management: weight-bearing exercise, smoking cessation, and adequate calcium and vitamin D.
That distinction matters because every bone drug carries some risk. Taking medication you don’t actually need means accepting side effects with minimal benefit. If your doctor diagnosed osteopenia but your fracture risk is low to moderate, the safest “drug” is really a combination of resistance training, walking, and making sure your nutrition supports bone health.
Oral Bisphosphonates: The Standard First Choice
When medication is needed, the American Association of Clinical Endocrinologists recommends alendronate, risedronate, zoledronic acid, or denosumab as first-line options, all backed by the strongest level of evidence (Grade A). For osteopenia specifically, oral bisphosphonates like alendronate and risedronate are the most commonly prescribed because they’re taken as pills, have decades of safety data, and work well at the lower fracture-risk levels typical of osteopenia.
These drugs slow bone breakdown by reducing the activity of cells that dissolve old bone tissue. They build up in bone over time and continue working even after you stop taking them, which is a meaningful safety advantage. It means you can take a “drug holiday” after several years rather than staying on medication indefinitely.
The most common complaints with oral bisphosphonates are digestive: nausea, heartburn, and abdominal pain. Interestingly, clinical trials have consistently shown that the rate of these symptoms isn’t significantly different between bisphosphonates and placebo pills. That said, real-world digestive discomfort is still the most frequently cited reason people stop taking them. You can minimize this by taking the pill first thing in the morning on an empty stomach, with a full glass of water, and staying upright for at least 30 minutes afterward.
Rare but Serious Bisphosphonate Risks
Two rare side effects get a lot of attention: osteonecrosis of the jaw (where a section of jawbone loses blood supply and deteriorates) and atypical femoral fractures (unusual breaks in the thigh bone). Both are genuinely rare with oral bisphosphonates. Jaw osteonecrosis occurs in roughly 1 in 10,000 to 1 in 100,000 patient-years of oral bisphosphonate use. Atypical femoral fractures occur at a rate of about 0.56 per 10,000 patient-years in people treated for less than three years, rising to 13.1 per 10,000 patient-years in those treated beyond eight years.
That duration-dependent increase is why drug holidays exist. After three to five years on a bisphosphonate, your doctor may recommend stopping the drug for a period, especially if your fracture risk is moderate rather than high. Because bisphosphonates stay embedded in bone, their protective effect lingers during the break. The FDA has acknowledged that drug holidays may be appropriate for lower-risk patients, though the optimal timing and length remain individualized.
One hard contraindication worth knowing: the intravenous bisphosphonate zoledronic acid should not be used if kidney filtration is below 35 mL/min. Oral bisphosphonates also require adequate kidney function, so if you have chronic kidney disease, your doctor will need to adjust the approach.
How Raloxifene Compares
Raloxifene is a selective estrogen receptor modulator, meaning it mimics estrogen’s bone-protective effects in certain tissues. Guidelines place it as a second- or third-line option for postmenopausal women. It has a notable bonus: it reduces the risk of invasive breast cancer by about 71% in postmenopausal women with osteoporosis, primarily by cutting estrogen-receptor-positive cancers by 80%. For a postmenopausal woman with both osteopenia and elevated breast cancer risk, this dual benefit can shift the safety calculus.
A large comparative study of over 320,000 patients found that raloxifene had a lower rate of atypical femoral fractures than alendronate (0.69 vs. 1.14 per 1,000 person-years), and alendronate users had a 51% higher risk of this complication. Rates of jaw osteonecrosis and esophageal cancer were similarly low with both drugs.
The trade-off is blood clots. Raloxifene roughly doubles the risk of deep vein thrombosis and pulmonary embolism compared to no treatment. In clinical trials, about 1 in 100 women treated with raloxifene experienced a blood clot event over an average of 2.6 years, with the highest risk in the first few months. If you have any history of blood clots, or if you’re facing a period of immobility like surgery or a long flight, raloxifene is not the right choice.
Why “Safest” Depends on Your Health Profile
There is no single safest drug for everyone with osteopenia. The best option depends on factors that vary from person to person. If you have a history of acid reflux or esophageal problems, oral bisphosphonates may cause more digestive issues, and raloxifene or an injected option could be preferable. If you have a history of blood clots, raloxifene is contraindicated and bisphosphonates are the safer path. If you have significant kidney impairment, certain bisphosphonates are off the table entirely. If you’re a postmenopausal woman with elevated breast cancer risk, raloxifene’s cancer-prevention benefit adds a safety dimension that bisphosphonates can’t match.
For the broadest population of people with osteopenia who need treatment, oral bisphosphonates (particularly alendronate and risedronate) offer the best-studied safety profile, the longest track record, the option of drug holidays, and strong fracture prevention. That’s why they remain the default first-line recommendation.
Calcium and Vitamin D as the Foundation
Regardless of whether you take a prescription medication, calcium and vitamin D form the foundation of bone health in osteopenia. These aren’t just nice-to-haves; bone drugs work poorly without adequate levels of both.
Safe upper limits are important here because more is not better. For adults over 50, the tolerable upper intake for calcium is 2,000 mg per day from all sources (food plus supplements), down from 2,500 mg for younger adults. The primary concern with excess calcium is kidney stones. For vitamin D, the upper limit is 4,000 IU per day for all adults. Most people with osteopenia are advised to get 1,000 to 1,200 mg of calcium daily (ideally from food first, with supplements filling the gap) and 800 to 1,000 IU of vitamin D, though your doctor may recommend more if your blood levels are low.
Getting calcium from food sources like dairy, leafy greens, and fortified foods is generally preferable to large supplement doses. Splitting calcium supplements into doses of 500 mg or less improves absorption and reduces the chance of digestive side effects.